China Resources Double-Crane cancels restricted shares after performance failures

China Resources Double-Crane Pharmaceutical announced the repurchase and cancellation of 79,013 restricted shares from its 2021 incentive plan for RMB 660,000.

The action follows seven incentive recipients no longer meeting conditions, including five failing to meet performance targets for the second vesting period, one retirement, and one organizational transfer.

The company plans to complete the cancellation by July 30, 2025, reducing total share capital by 79,013 shares to 1,038,757,509 shares.